ProMIS Neurosciences (PMN) has shared an update.
ProMIS Neurosciences Inc. reported promising preliminary results from its Phase 1a clinical trial for PMN310, a potential Alzheimer’s treatment, showing good tolerance in healthy volunteers without serious adverse events. The drug demonstrated dose-proportional levels in cerebrospinal fluid, hinting at once-monthly dosing viability. With the last cohort’s data pending, the company anticipates consistent outcomes and is preparing for the next trial phase, aiming to present comprehensive findings later in the year.
See more insights into PMN stock on TipRanks’ Stock Analysis page.
